Wells Fargo & Company MN lessened its stake in Voyager Therapeutics Inc (NASDAQ:VYGR) by 6.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 339,799 shares of the company’s stock after selling 22,134 shares during the quarter. Wells Fargo & Company MN owned about 0.92% of Voyager Therapeutics worth $9,250,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of the stock. Clearbridge Investments LLC increased its stake in Voyager Therapeutics by 93,030.6% during the first quarter. Clearbridge Investments LLC now owns 379,973 shares of the company’s stock worth $7,273,000 after acquiring an additional 379,565 shares during the last quarter. Bailard Inc. acquired a new stake in shares of Voyager Therapeutics in the second quarter valued at $1,116,000. Spark Investment Management LLC grew its stake in shares of Voyager Therapeutics by 18.5% in the first quarter. Spark Investment Management LLC now owns 146,200 shares of the company’s stock valued at $2,798,000 after buying an additional 22,800 shares in the last quarter. Strs Ohio acquired a new stake in shares of Voyager Therapeutics in the second quarter valued at $574,000. Finally, Raymond James Financial Services Advisors Inc. grew its stake in shares of Voyager Therapeutics by 10.6% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 202,682 shares of the company’s stock valued at $3,879,000 after buying an additional 19,481 shares in the last quarter. 78.50% of the stock is owned by hedge funds and other institutional investors.
NASDAQ VYGR traded up $0.24 during trading on Friday, reaching $17.21. 3,898 shares of the company’s stock were exchanged, compared to its average volume of 331,692. The stock has a market cap of $633.84 million, a P/E ratio of -6.26 and a beta of 2.63. The company has a 50 day moving average price of $19.98 and a two-hundred day moving average price of $21.55. Voyager Therapeutics Inc has a 1 year low of $7.76 and a 1 year high of $28.79.
A number of equities research analysts have recently weighed in on the company. Morgan Stanley lifted their price objective on Voyager Therapeutics from $21.00 to $28.00 and gave the company an “equal weight” rating in a research note on Friday, July 12th. Nomura reiterated a “buy” rating and issued a $37.00 target price on shares of Voyager Therapeutics in a report on Tuesday, August 13th. BidaskClub lowered Voyager Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 27th. Wedbush lifted their target price on Voyager Therapeutics from $27.00 to $36.00 and gave the company an “outperform” rating in a report on Tuesday, June 18th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $26.00 price target on shares of Voyager Therapeutics in a report on Monday, August 12th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the company. Voyager Therapeutics currently has an average rating of “Buy” and an average target price of $27.50.
About Voyager Therapeutics
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease.
Featured Story: Buyback
Want to see what other hedge funds are holding VYGR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Voyager Therapeutics Inc (NASDAQ:VYGR).
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.